10/507044 15 Rec'd PCT/PTO 09 SEP 2004.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

Based on PCT/JP03/02783

Filed:

Intl. Filing 10 MARCH 2003

1st Inventor:

Takahito HARA

For:

Remedies for Sex Hormone-Dependent Disease

Atty. Dkt. No.

3033 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

MAIL STOP PCT P.O. Box 1450 Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached Forms PTO/SB/08A and 08B. A legible copy of each listed reference is herewith being provided to the Examiner.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

Dated:

170

(071) 303-3312

(847) 383-3391

Respectfully submitted,


Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1	1449/PTO		Complete if Known		
			Application Number -	Based on PCT/JP03/02783	
INICODMA	ATION DI	SCLOSURE	Filing Date	Intl. Filing 10 MARCH 2003	
			First Named Inventor	HARA, Takahito	
		APPLICANT	Art Unit	tba	
(Use as many sheets as necessary)			Examiner Name	tba	
Sheet 1	of	2	Attorney Docket Number	3033 US0P	

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
	NO.	Number-Kind Code ^{2 (# known)}	WAVE-DD-1111	Applicant of Cited Document	Figures Appear
	A1	^{US-} 4,472,382	09/18/1984	F. Labrie, et al.	
_		US-			
		US-		1	
		US-			
		US-		-	
		US-			
		US-			
		US-			
		US-			
	 	US-			

Examiner Cite Initials* No.	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A2	WO 90/10462	09/20/1990	Endorecherche Inc.		V
_	A3	EP 0413209 A1	02/20/1991	Abbott Laboratories		V
	A4	WO 96/40150	12/19/1996	Merck & Co., Inc.		V
	A5	WO 00/57892-Abstract only	10/05/2000	Pierre Fabre Medicament		

Examiner	Date	
Signature	Considered	
Olghature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	Based on PCT/JP03/02783	
INFORMATION DISCLOSURE	Filing Date	Intl. Filing 10 MARCH 2003	
STATEMENT BY APPLICANT	First Named Inventor	HARA, Takahito	
(Use as many sheets as necessary)	Art Unit	tba	
(030 as many should as nocessary)	Examiner Name	tba	
Sheet 2 of 2	Attorney Docket Number	3033 US0P	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A6	J. KOKONTIS, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation", Cancer Res., (1994), pp. 1566-1573, Vol. 54.	8
	A7	Y. UMEKITA, et al., "Human Prostate Tumor Growth in Athymic Mice: Inhibition by Androgens and Stimulation by Finasteride", Proc. Natl. Acad. Sci. USA, (1996), pp. 11802-11807, Vol. 93.	8
	•		
		·	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	Substitute for form 1449/PTO		Complete if Known		
Coosino	10 10 10 11 1440 170			Application Number	Based on PCT/JP03/02783
INFO	DRMATION	DIS	SCLOSURE	Filing Date	Intl. Filing 10 MARCH 2003
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	HARA, Takahito
(Use as many sheets as necessary)				Art Unit	tba
				Examiner Name	tba
Sheet	2	of	2	Attorney Docket Number	3033 US0P

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A6	J. KOKONTIS, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation", Cancer Res., (1994), pp. 1566-1573, Vol. 54.	V
	A7	Y. UMEKITA, et al., "Human Prostate Tumor Growth in Athymic Mice: Inhibition by Androgens and Stimulation by Finasteride", Proc. Natl. Acad. Sci. USA, (1996), pp. 11802-11807, Vol. 93.	V

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Committee to complete this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.